Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Breast Cancer

  Free Subscription


18.08.2025

1 AJR Am J Roentgenol
1 Am J Clin Pathol
1 Ann Surg
11 Ann Surg Oncol
6 BMC Cancer
3 Breast Cancer
1 Breast Cancer (Auckl)
5 Breast Cancer Res
3 Breast Cancer Res Treat
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Res
3 Clin Breast Cancer
2 Clin Cancer Res
1 Eur J Cancer
1 Eur J Surg Oncol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Biol Chem
1 J Clin Invest
2 J Clin Oncol
4 J Natl Cancer Inst
1 J Pathol
1 J Surg Oncol
2 Lancet
1 Mod Pathol
3 NPJ Breast Cancer
1 PLoS Comput Biol
1 PLoS One
1 Radiol Artif Intell
1 Radiology
1 Radiother Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. THOMAS M
    Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer: Who Truly Benefits?
    AJR Am J Roentgenol. 2025 Aug 13. doi: 10.2214/AJR.25.33698.
    PubMed        


    Am J Clin Pathol

  2. ZILENAITE-PETRULAITIENE D, Rasmusson A, Valkiuniene RB, Laurinaviciene A, et al
    Reproducibility of Ki67 Haralick entropy as a prognostic marker in estrogen receptor-positive HER2-negative breast cancer.
    Am J Clin Pathol. 2025 Aug 9:aqaf081. doi: 10.1093.
    PubMed         Abstract available


    Ann Surg

  3. EL MOHEB M, Putman K, Sears O, Kibbe MR, et al
    An Open-architecture AI Model for CPT Coding in Breast Surgery: Development, Validation, and Prospective Testing.
    Ann Surg. 2025;282:439-448.
    PubMed         Abstract available


    Ann Surg Oncol

  4. BLEICHER RJ
    ASO Author Reflections: The Worried Waiting-Breast Cancer Upstaging and In Vivo Growth During Preoperative Delays.
    Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-18008.
    PubMed        

  5. CHEN SL, Shah C, Boyages J, Koelmeyer L, et al
    ASO Visual Abstract: The Importance of a Pretreatment Baseline When Screening Patients for Breast-Cancer-Related Lymphedema.
    Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-18062.
    PubMed        

  6. NAASEH A, Margenthaler JA
    ASO Author Reflections: Moving Beyond Risk-Based Genetic Testing Criteria: Supporting Universal Genetic Testing in Breast Cancer Patients.
    Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-18074.
    PubMed        

  7. KERIVAN LT, Larson KE
    ASO Author Reflections: Unilateral Cancer, Bilateral Decisions: Contralateral Risk-Reducing Mastectomy Performance in Patients with a First Breast Cancer and Positive Genetic Testing.
    Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-18016.
    PubMed        

  8. LIN Y, Wang YY, Xu ZB, Dong L, et al
    ASO Author Reflections: MicroRNAs as Predictive Biomarkers for Axillary Lymph Node Metastasis in Breast Cancer.
    Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-18075.
    PubMed        

  9. LIN Y, Wang YY, Xu ZB, Dong L, et al
    miRNAs Associated with Axillary Lymph Node Metastasis in Breast Cancer: A Systematic Review and Meta-Analysis.
    Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-17983.
    PubMed         Abstract available

  10. KERIVAN L, Wagner J, Nye L, Balanoff C, et al
    ASO Visual Abstract: Surgical Choice Among Women with a First Breast Cancer and Pathogenic Variants in Breast Cancer Genes.
    Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-18071.
    PubMed        

  11. THOMPSON D, Fefferman M, Simovic S, Kuchta K, et al
    Impact of Quality Improvement Interventions on Biopsy-to-Treatment Time in Breast Cancer: Results from the PROMPT Quality Collaborative of the National Accreditation Program for Breast Centers.
    Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-17935.
    PubMed         Abstract available

  12. YI M, Chavez-MacGregor M, Smith BD, Mitchell MP, et al
    Comparing Survival Differences between Patients Undergoing Breast-Conserving Therapy Versus Total Mastectomy as a First Treatment for Early Stage Breast Cancer.
    Ann Surg Oncol. 2025 Aug 11:10.1245/s10434-025-18030.
    PubMed         Abstract available

  13. LEE EG, Lee DE, Jung SY, Han JH, et al
    ASO Author Reflections: Multimodal Sentinel Lymph Node Mapping in Breast Cancer: Efficacy and Clinical Implications After Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2025 Aug 12. doi: 10.1245/s10434-025-18053.
    PubMed        

  14. TASHJIAN NL, Hoskin TL, Leon-Ferre RA, Boughey JC, et al
    The Association of Clinical Stage at Presentation with Overall Survival of Patients who have HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2025 Aug 14. doi: 10.1245/s10434-025-18050.
    PubMed         Abstract available


    BMC Cancer

  15. OLSON R, Cua M, Matthews Q, Laing J, et al
    Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB).
    BMC Cancer. 2025;25:1285.
    PubMed         Abstract available

  16. JANG MK, Park S, Jeon JY, Kang MJ, et al
    Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial.
    BMC Cancer. 2025;25:1296.
    PubMed         Abstract available

  17. LEE J, Ahn HK, Lee KH, Jung KH, et al
    Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemother
    BMC Cancer. 2025;25:1295.
    PubMed         Abstract available

  18. FU J, Deng S, Zheng W, Zheng C, et al
    Construction of a transfer learning-based depression detection model for female breast cancer patients: text sentiment analysis.
    BMC Cancer. 2025;25:1307.
    PubMed         Abstract available

  19. MARIOSA D, Ponzano M, Grotta A, Lagerros YT, et al
    Dietary non-enzymatic antioxidant capacity and risk of breast cancer: the Swedish National March Cohort.
    BMC Cancer. 2025;25:1310.
    PubMed         Abstract available

  20. QIN JN, Dai WB, Zhang WH, Chen BJ, et al
    Identification of optimal biomarkers associated with distant metastasis in breast cancer using Boruta and Lasso machine learning algorithms.
    BMC Cancer. 2025;25:1311.
    PubMed         Abstract available


    Breast Cancer

  21. NAHLS NS, Carpen T, Nuutinen M, Saarto T, et al
    The impact of specialist palliative care on healthcare utilization among patients with breast cancer: a nationwide register-based cohort study.
    Breast Cancer. 2025 Aug 14. doi: 10.1007/s12282-025-01759.
    PubMed         Abstract available

  22. MUHAMMAD UK, Sulyman SB, Saleh I, Gwarzo MY, et al
    Association of adiponectin gene polymorphism with adipokine and lipid profile in breast cancer patients from Kano, Nigeria.
    Breast Cancer. 2025 Aug 13. doi: 10.1007/s12282-025-01758.
    PubMed         Abstract available

  23. TAWFILES D, Chen J, Tawfiles M, Jones S, et al
    Female breast cancer burden among adolescent and young adults in North Africa.
    Breast Cancer. 2025 Aug 9. doi: 10.1007/s12282-025-01755.
    PubMed         Abstract available


    Breast Cancer (Auckl)

  24. SHAFFER K, Harris L, Gentile L, Merrill A, et al
    The Role of Axillary Lymph Node Dissection in Breast Cancer Patients With Residual Nodal Disease After Receiving Neoadjuvant Chemotherapy.
    Breast Cancer (Auckl). 2025;19:11782234251352996.
    PubMed         Abstract available


    Breast Cancer Res

  25. HAYASHI K, Hoshii T, Ning M, Matsumoto M, et al
    Non-enzymatic SETD1A activity drives breast cancer cell proliferation via cyclin K.
    Breast Cancer Res. 2025;27:142.
    PubMed         Abstract available

  26. RAVANI LV, Bagheri Z, Brufsky AM, Michellon I, et al
    Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2025;27:146.
    PubMed         Abstract available

  27. SLEDGE GWJ, Xiu J, Solzak JP, Ribeiro J, et al
    Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis.
    Breast Cancer Res. 2025;27:144.
    PubMed         Abstract available

  28. PARISSENTI AM, Pritzker LB, Dahle MA, Gythfeldt HVL, et al
    High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.
    Breast Cancer Res. 2025;27:143.
    PubMed         Abstract available

  29. HUANG B, Zhang Y, Chen Z, Yuan Y, et al
    Exosome-delivered METTL14 drives hypoxia-induced proliferation, metastasis, and glycolysis of breast cancer cells through regulating TRIM16-mediated FGF7 ubiquitination.
    Breast Cancer Res. 2025;27:145.
    PubMed         Abstract available


    Breast Cancer Res Treat

  30. GONZALO-ENCABO P, Giobbie-Hurder A, Sears DD, Mayer EL, et al
    Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study.
    Breast Cancer Res Treat. 2025 Aug 12. doi: 10.1007/s10549-025-07803.
    PubMed         Abstract available

  31. BAKHUIS CFJ, Prekovic S, Suelmann BBM, Verloop J, et al
    Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort.
    Breast Cancer Res Treat. 2025 Aug 12. doi: 10.1007/s10549-025-07806.
    PubMed         Abstract available

  32. MATA DGMM, Sutradhar R, Castelo M, Hahn E, et al
    Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis.
    Breast Cancer Res Treat. 2025 Aug 13. doi: 10.1007/s10549-025-07778.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  33. BOROWSKY PA, Nahodyl L, Sable S, Sierra MA, et al
    Residential Proximity to NPL Superfund Sites and High Particulate Matter Exposure is Associated with Increased Likelihood of Triple Negative Breast Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available

  34. TELONIS AG, Hernandez AE, Borowsky PA, Reguero Hernandez ED, et al
    Molecular Portraits of Social Adversity in Breast Cancer: Neighborhood Disadvantage is Associated with Epigenetic Deregulation of Key Oncogenic Pathways.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available


    Cancer Res

  35. RINKENBAUGH AL, Qi Y, Cai S, Shao J, et al
    An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naive and Longitudinal Samples During Neoadjuvant Chemotherapy.
    Cancer Res. 2025 Aug 13. doi: 10.1158/0008-5472.CAN-24-5023.
    PubMed         Abstract available


    Clin Breast Cancer

  36. FAN YJ, Xu HQ, Li H, Zhang ZR, et al
    Effects of Resistance Training at Different Intensities on Preventing Breast Cancer-Related Lymphedema: A 1-Year Randomized Controlled Trial.
    Clin Breast Cancer. 2025 Jul 14:S1526-8209(25)00206.
    PubMed         Abstract available

  37. MOLLER AL, Borgquist S, Skarping I
    Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer.
    Clin Breast Cancer. 2025 Jun 26:S1526-8209(25)00179.
    PubMed         Abstract available

  38. CIVIL YA, Purcell ND, de Vries R, Oei AL, et al
    Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer Patients Treated With Radiotherapy: A Systematic Review of Literature.
    Clin Breast Cancer. 2025 Jul 17:S1526-8209(25)00200.
    PubMed         Abstract available


    Clin Cancer Res

  39. KJELDSTED E, Ammitzboll G, Laenkholm AV, Rasic D, et al
    Effects of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer (Neo-train): a randomised controlled trial.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0416.
    PubMed         Abstract available

  40. BAIRD RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, et al
    Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-1198.
    PubMed         Abstract available


    Eur J Cancer

  41. MICHEL LL, Ziegler P, Kreis P, Hartkopf AD, et al
    Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
    Eur J Cancer. 2025;227:115689.
    PubMed         Abstract available


    Eur J Surg Oncol

  42. ZABOROWSKI AM, McGarry J, Wehrmann F, Ryan EJ, et al
    Oncological outcomes of sentinel lymph node biopsy alone in patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
    Eur J Surg Oncol. 2025;51:110356.
    PubMed         Abstract available


    Int J Cancer

  43. WU X, Qu F, Hua Y, Lu R, et al
    An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancer.
    Int J Cancer. 2025 Aug 11. doi: 10.1002/ijc.70079.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  44. YADAV DBS, Goyal DS, Dahiya DD, Vias DP, et al
    HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): Acute toxicity results.
    Int J Radiat Oncol Biol Phys. 2025 Aug 6:S0360-3016(25)06045.
    PubMed         Abstract available


    J Biol Chem

  45. SONG H, Peng J, Niu Z, Liu X, et al
    A non-coding RNA circGNAI2 suppresses triple-negative breast cancer progression by sponging miR-454-3p to inhibit the VGLL4-STAT3 signaling.
    J Biol Chem. 2025 Aug 8:110577. doi: 10.1016/j.jbc.2025.110577.
    PubMed         Abstract available


    J Clin Invest

  46. KIM S, Son E, Park HR, Kim M, et al
    Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer models.
    J Clin Invest. 2025 Aug 12:e188839. doi: 10.1172/JCI188839.
    PubMed         Abstract available


    J Clin Oncol

  47. GAO JJ, Prowell TM, Gittleman H, Cheng J, et al
    US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
    J Clin Oncol. 2025 Aug 11:JCO2500167. doi: 10.1200/JCO-25-00167.
    PubMed         Abstract available

  48. JERZAK KJ, Warner E, Knisely JPS, Sahgal A, et al
    Brain Imaging Surveillance for Patients With Metastatic Breast Cancer: A Randomized Clinical Trial Is Required to Guide Practice.
    J Clin Oncol. 2025 Aug 13:JCO2500356. doi: 10.1200/JCO-25-00356.
    PubMed        


    J Natl Cancer Inst

  49. WEI Y, Castro E, Yin K, Zhang M, et al
    Ambient air pollution and mortality in older breast cancer patients.
    J Natl Cancer Inst. 2025 Aug 5:djaf217. doi: 10.1093.
    PubMed         Abstract available

  50. MO T, Partridge A, Joffe M, Cubasch H, et al
    Survival deficits in young women with breast cancer in Sub-Saharan africa: the ABC-DO cohort.
    J Natl Cancer Inst. 2025 Aug 7:djaf213. doi: 10.1093.
    PubMed         Abstract available

  51. LAMBERTINI M, Allegranza D, Laubender RP, Harbeck N, et al
    Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
    J Natl Cancer Inst. 2025 Aug 12:djaf198. doi: 10.1093.
    PubMed         Abstract available

  52. TARANTINO P, Lee D, Foldi J, Soulos PR, et al
    Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
    J Natl Cancer Inst. 2025 Aug 14:djaf220. doi: 10.1093.
    PubMed         Abstract available


    J Pathol

  53. NGUYEN KA, McLemore LE, Ke Y, DePledge LN, et al
    Activation of PI3K and deletion of p53 in keratin 15-expressing mouse mammary cells induces tumor heterogeneity and plasticity modeling metaplastic breast cancer.
    J Pathol. 2025 Aug 13. doi: 10.1002/path.6463.
    PubMed         Abstract available


    J Surg Oncol

  54. LIU P, Liu Y, Xie Y, Hu S, et al
    Potential of Combination of CE-MRI and Serum Her-2neu Extracellular Domain in Evaluating Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer.
    J Surg Oncol. 2025 Aug 11. doi: 10.1002/jso.70058.
    PubMed         Abstract available


    Lancet

  55. HOWELL SJ, Palmieri C
    Extending aromatase inhibitor treatment in early breast cancer; longer is better for many.
    Lancet. 2025;406:573-575.
    PubMed        


  56. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    PubMed         Abstract available


    Mod Pathol

  57. SCHILDHAUS HU, Badve S, D'Arrigo C, Farshid G, et al
    A Global Ring Study: Concordance Between Ventana PATHWAY anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-low Breast Cancer.
    Mod Pathol. 2025 Aug 9:100867. doi: 10.1016/j.modpat.2025.100867.
    PubMed         Abstract available


    NPJ Breast Cancer

  58. KUMAR R, Duyar-Ayerdi S, Sundaresan A, Srinivasasainagendra V, et al
    Race-related host and microbe transcriptomic signatures in triple-negative breast cancer.
    NPJ Breast Cancer. 2025;11:87.
    PubMed         Abstract available

  59. FENG Y, Xiong A, Mulay O, Sokolova A, et al
    Integrated profiling of metaplastic breast cancer identifies putative master regulators of intratumoral heterogeneity.
    NPJ Breast Cancer. 2025;11:89.
    PubMed         Abstract available

  60. GORMLEY M, Lawrence WR, Plascak JJ, Paskett ED, et al
    A Society-to-Cells approach to evaluating multilevel and interrelated drivers of breast cancer disparities in Black women.
    NPJ Breast Cancer. 2025;11:90.
    PubMed         Abstract available


    PLoS Comput Biol

  61. YAVUZ BR, Sahin U, Jang H, Nussinov R, et al
    Mutations in tumor signaling, metastases, and synthetic lethality establish distinct patterns.
    PLoS Comput Biol. 2025;21:e1013351.
    PubMed         Abstract available


    PLoS One

  62. VEZZANI F, Cabieses B, Obach A, Torrealba S, et al
    Unmet supportive care needs of young women with breast cancer in Chile during follow-up stage after treatment: A qualitative study.
    PLoS One. 2025;20:e0330166.
    PubMed         Abstract available


    Radiol Artif Intell

  63. KOC U, Karakas E, Sezer EA, Besler MS, et al
    MammosighTR: Nationwide Breast Cancer Screening Mammogram Dataset with BI-RADS Annotations for Artificial Intelligence Applications.
    Radiol Artif Intell. 2025 Aug 13:e240841. doi: 10.1148/ryai.240841.
    PubMed         Abstract available


    Radiology

  64. CHEN Y, Partridge GJW, Vazirabad M, Ball RL, et al
    Performance of Algorithms Submitted in the 2023 RSNA Screening Mammography Breast Cancer Detection AI Challenge.
    Radiology. 2025;316:e241447.
    PubMed         Abstract available


    Radiother Oncol

  65. OLIVEROS S, Goyal A, Dodwell D
    The impact of radiotherapy on trials of axillary management in early breast cancer.
    Radiother Oncol. 2025 Aug 6:111054. doi: 10.1016/j.radonc.2025.111054.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.